Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2016 - 2018)

Ani Pharmaceuticals' Change in Accured Expenses history spans 9 years, with the latest figure at $1.0 million for Q3 2018.

  • For Q3 2018, Change in Accured Expenses fell 43.14% year-over-year to $1.0 million; the TTM value through Sep 2018 reached $174000.0, up 74.0%, while the annual FY2017 figure was $644000.0, 31.49% down from the prior year.
  • Change in Accured Expenses for Q3 2018 was $1.0 million at Ani Pharmaceuticals, up from -$749000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.8 million in Q3 2017 and bottomed at -$1.9 million in Q4 2015.
  • The 5-year median for Change in Accured Expenses is $143000.0 (2014), against an average of $171473.7.
  • The largest annual shift saw Change in Accured Expenses tumbled 523.08% in 2015 before it soared 45125.0% in 2017.
  • A 5-year view of Change in Accured Expenses shows it stood at -$630000.0 in 2014, then tumbled by 198.57% to -$1.9 million in 2015, then increased by 8.88% to -$1.7 million in 2016, then soared by 31.74% to -$1.2 million in 2017, then soared by 187.52% to $1.0 million in 2018.
  • Per Business Quant, the three most recent readings for ANIP's Change in Accured Expenses are $1.0 million (Q3 2018), -$749000.0 (Q2 2018), and $1.1 million (Q1 2018).